

OPEN ACCESS

EDITED BY

Vânia Pobre,
Universidade Nova de Lisboa, Portugal

REVIEWED BY

Thuy Do,
University of Leeds, United Kingdom
Camille Zenobia,
AbbVie, United States

*CORRESPONDENCE

Alex Mira

✉ mira_ale@gva.es

María D. Ferrer

✉ maria.ferrer@fisabio.es

RECEIVED 04 October 2023

ACCEPTED 29 November 2023

PUBLISHED 18 December 2023

CITATION

Žiemyté M, Lopez-Roldan A, Carda-Diéguez M, Reglero-Santaolaya M, Rodríguez A, Ferrer MD and Mira A (2023) Personalized antibiotic selection in periodontal treatment improves clinical and microbiological outputs. *Front. Cell. Infect. Microbiol.* 13:1307380. doi: 10.3389/fcimb.2023.1307380

COPYRIGHT

© 2023 Žiemyté, Lopez-Roldan, Carda-Diéguez, Reglero-Santaolaya, Rodríguez, Ferrer and Mira. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Personalized antibiotic selection in periodontal treatment improves clinical and microbiological outputs

Miglé Žiemyté¹, Andrés Lopez-Roldan², Miguel Carda-Diéguez¹, Marta Reglero-Santaolaya², Ana Rodríguez², María D. Ferrer^{1*} and Alex Mira^{1,3*}

¹Genomics & Health Department, Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO) Foundation, Valencia, Spain, ²Department of Stomatology, Faculty of Medicine and Dentistry, University of Valencia, Valencia, Spain, ³School of Health and Welfare, Jönköping University, Jönköping, Sweden

Introduction: Periodontitis is a biofilm-mediated disease that is usually treated by non-surgical biofilm elimination with or without antibiotics. Antibiotic treatment in periodontal patients is typically selected empirically or using qPCR or DNA hybridization methods. These approaches are directed towards establishing the levels of different periodontal pathogens in periodontal pockets to infer the antibiotic treatment. However, current methods are costly and do not consider the antibiotic susceptibility of the whole subgingival biofilm.

Methods: In the current manuscript, we have developed a method to culture subgingival samples *ex vivo* in a fast, label-free impedance-based system where biofilm growth is monitored in real-time under exposure to different antibiotics, producing results in 4 hours. To test its efficacy, we performed a double-blind, randomized clinical trial where patients were treated with an antibiotic either selected by the hybridization method (n=32) or by the one with the best effect in the *ex vivo* growth system (n=32).

Results: Antibiotic selection was different in over 80% of the cases. Clinical parameters such as periodontal pocket depth, attachment level, and bleeding upon probing improved in both groups. However, dental plaque was significantly reduced only in the group where antibiotics were selected according to the *ex vivo* growth. In addition, 16S rRNA sequencing showed a larger reduction in periodontal pathogens and a larger increase in health-associated bacteria in the *ex vivo* growth group.

Discussion: The results of clinical and microbiological parameters, together with the reduced cost and low analysis time, support the use of the impedance system for improved individualized antibiotic selection.

KEYWORDS

xCELLigence, biofilms, personalized medicine, periodontitis, oral bacteria, infection, antibiotic treatment, subgingival plaque

Introduction

Biofilms are defined as bacterial communities composed of single or various bacterial species attached to each other on biotic/abiotic surfaces and encased in a self-secreted extracellular polymeric substance (EPS) (Seneviratne et al., 2008; Lu et al., 2019). For instance, oral biofilms such as dental plaque are composed of several hundred species firmly attached to the teeth above (supragingival dental plaque) or below the gum line (subgingival dental plaque) (Kuboniwa and Lamont, 2010; Checchi and Pascolo, 2018; Lamont et al., 2018). Oral biofilms are strongly associated with the occurrence and the progression of oral diseases such as dental caries, gingivitis, periodontitis and halitosis (Rosier et al., 2018; Johnston et al., 2021). Gingivitis is a reversible inflammatory lesion resulting from interactions between the subgingival dental plaque and the host's immune-inflammatory response, which remains contained within the gingiva and does not extend to the periodontal attachment. Contrarily, periodontitis is a chronic multifactorial inflammatory disease associated with dysbiotic subgingival biofilms and characterized by progressive destruction of the tooth-supporting apparatus, which can eventually lead to its loss (Chapple et al., 2015; Nilsson et al., 2018; Papapanou et al., 2018). In addition, there exist many different factors that contribute enormously to the occurrence and development of this disease, including mechanical disruption of gums, tobacco smoking, pathogen infection, deficient oral hygiene and the failure of immune homeostasis (Darveau, 2010; Aljehani, 2014).

Despite the significant advances in the treatment of periodontal diseases, this pathology continues to increase, being the sixth-most common prevalent condition in the world. In fact, lack of adequate treatment and proper personal hygiene have been suggested as the potential causes of the aggravation of the disease (Marcenes et al., 2013). Although subgingival dental plaque elimination by radical scraping reduces inflammation, inflammation may return with time, especially in high-risk individuals. For this reason, the combination of mechanical treatment and systemic antibiotics or antiseptics is commonly used, although the specific cases where this is recommended vary among countries (Chapple et al., 2015; Feres et al., 2015; Isola, 2020). For instance, due to concerns about patient's health and the impact of overuse of antibiotics in the emergence of resistance, their routine use as an adjunct to subgingival debridement in patients with periodontitis is not recommended by the European Federation of Periodontology (Sanz et al., 2020). Many authors recommend the adjunctive use of specific systemic antibiotics for some patient categories (e.g. generalized periodontitis Stage III in young adults) (Teughels et al., 2020). In order to choose an effective antibiotic therapy in each particular case, different PCR and DNA probe hybridization techniques based on the quantification of periodontal bacteria have been developed. Private laboratories usually use Socransky's complex-based (purple, red, orange, yellow, and green) detection and quantification of periodontal pathogens, including *Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis*, *Tannerella forsythia* and *Treptononema denticola* among others (Ko et al., 2021; Van der Weijden et al., 2021).

However, these techniques are expensive and only consider the presence of specific bacterial species rather than the antibiotic effect on the whole biofilm (where some bacterial strains can be susceptible and others resistant to a given antibiotic) (Heller et al., 2011). Moreover, these molecular genetic techniques overlook the interaction between different communities and the presence of EPS which can protect biofilm-embedded bacteria (Jiao et al., 2014; Lu et al., 2020; Jakubovics et al., 2021). Thus, all mentioned limitations of currently used methods for antibiotic selection for periodontal disease can lead to treatment failure and consequently to other serious health complications, including bacteremia, pre-mature birth, cardiovascular diseases, or autoimmune diseases, among others (Li et al., 2000; Irshad et al., 2020). Therefore, there is a need to develop new, faster, inexpensive, and more reliable methodologies able to predict the best individualized antibiotic treatment for patients with periodontal disease, in those cases and countries where this is appropriate.

In the current manuscript, we used Real-Time Cell Analysis (RTCA) to evaluate the *in vitro* antibiotic effect on periodontal biofilm growth dynamics of 64 patients with severe periodontal disease. This method consists of growing fresh periodontal samples in a microcosm model where biofilm growth is monitored in real time using impedance-based measurements (Ferrer et al., 2007; Matilla-Cuenca et al., 2020). After that, in order to assess the efficacy of antibiotic use based on this method, a clinical trial was performed where half of the patients were treated with the antibiotic selected by this growth-based system, while the other half were treated with the antibiotic suggested by a standard methodology (hybridization-based antibiotic selection). One and two months after the antibiotic treatment, we compared the disease evolution by evaluation of clinical parameters (including periodontal pocket depth, clinical attachment loss, bleeding on probing and presence of plaque) and changes in subgingival plaque microbiological composition using 16S rRNA gene Illumina sequencing.

Materials and methods

Sample collection, transportation, and storage

To select the most suitable transport media and optimal storage time for periodontal biofilm samples, subgingival plaque from 5 individuals was collected by introducing 10 sterile paper-points (size 20) into the deepest subgingival pockets (≥ 6 mm) for 30-60 seconds and placed into 2 mL of three different transport media (RTF: Reduced Transport Fluid, VMG III: Viability Medium Goteborg without agar or agarose and VMG III-Agar: Viability Medium Goteborg with agar and agarose) that were prepared following Dahlen et al. (Dahlén et al., 1993). Samples were then immediately transported from the dental clinic to the laboratory and stored at room temperature for 24 and 48 h to determine the optimal conditions for their storage and recovery, based on bacterial composition similarity between the sample and the biofilm grown (Supplementary Figure 1).

Study design and patients' selection

To evaluate the use of the RTCA system in antibiotic selection for the individualized treatment of patients with periodontal disease, and to compare the *in vivo* effect of those antibiotics to the current antibiotic selection techniques, a randomized, double blind, parallel group clinical study was designed. The study protocol was reviewed and approved by the Ethics Committee of the University of Valencia (Spain) (H1547805836517). The study was conducted from September 2019 to May 2022.

Required sample size was calculated by a power estimation based on the differences in clinical attachment level (CAL) of 1 mm between the groups with variation in the population of 0.5, a confidence level of 80% and a power of 95%, which suggested a sample size of 20 individuals per group. Due to the length of the study and the multiple visits, a high dropout rate (>15%) was expected. Therefore, a final sample size of over 60 volunteers fulfilling the inclusion/exclusion criteria was estimated.

Inclusion criteria included: adults between 40 and 70 years old, non-smokers or smokers of less than 10 cigarettes a day, with stage III and IV grade A-B periodontitis, presence of at least 20 teeth in the mouth, including at least one molar per quadrant and good general health. Exclusion criteria included: smokers of more than 10 cigarettes a day, patients who have been treated with periodontal therapy in the last 12 months, patients who have been taking antibiotics in the last three months or who routinely used antiseptics in the previous month, patients who due to their systemic condition take antibiotics, pregnant or lactating woman, patients who take medication that might alter the immune system or bone metabolism, patients who are allergic to the antibiotics used in the study and people with diabetes with more than 7% glycosylated hemoglobin. After signing the informed consent form, clinical periodontal indexes such as bleeding on probing (BOP), probing depth (PD), clinical attachment level (CAL) and plaque presence (PLAQUE) were evaluated as previously described (O'Leary et al., 1972; Ainamo and Bay, 1975; Weinberg and Eskow, 2003). Following visits to the dental clinic are indicated in the flow diagram of the study design (Supplementary Figure 2).

After the evaluation of clinical parameters, the subgingival plaque samples of 64 volunteers were collected into VMG III transport media, as described above, for both biofilm growth monitoring in real-time (Real-Time culture; RT-Culture) using the xCELLigence impedance monitoring system (Agilent Technologies) and for bacterial composition determination before treatment. In parallel, subgingival plaque samples from the same volunteers were collected into sterile tubes using micro-IDent[®] plus11 kit (Hain Lifescience GmbH, Germany) and following the instructions provided by a private laboratory (Echevarne Laboratory, Barcelona, Spain) and sent immediately for PCR and specific probe hybridization-based quantification of 11 of the most common periodontal pathogenic species (*Aggregatibacter actinomycetemcomitans*, *Porphyromonas gingivalis*, *Tannerella forsythia*, *Treponema denticola*, *Prevotella intermedia*, *Peptostreptococcus micros*, *Fusobacterium nucleatum/periodonticum*, *Campylobacter rectus*, *Eubacterium nodatum*, *Eikenella corrodens* and *Capnocytophaga gingivalis/ochracea/sputigena*) and the

corresponding levels of five bacterial complexes based on Sockransky's classification (Urbán et al., 2010; Santigli et al., 2016). Patients were then randomly assigned to one of the two treatment groups: half of the patients (32 volunteers) were treated with the antibiotic selected by the *in vitro* culturing system using impedance-based results, while the other half were treated with the antibiotic selected by the hybridization methodology (32 volunteers).

After four and eight weeks of systemic antibiotic treatment, the patient's oral health was re-evaluated, including all clinical parameters described above (Supplementary Figure 2). In addition, new subgingival plaque samples were collected in VMG III transport media, as previously indicated, for the evaluation of the total bacterial composition after antibiotic treatment in both study groups (Figure 1). After the treatment, clinical and microbiological parameters were analyzed and compared between methodologies. Three patients of the RT-Culture group were not analyzed, as one of them took other antibiotic prescribed by another professional because of additional infection, and two failed to attend their 2-month reevaluation visit to the dental clinic because of COVID. Similarly, six patients from the hybridization group did not participate in all needed dental clinic visits, and five had incomplete or wrong antibiotic dosing (Supplementary Figure 3).

Randomization and blinding

A randomized, double-blind clinical trial was carried out where patients and dentists were unaware of which methodology was used to select the antibiotic as part of the periodontal therapy. In detail, after consent form approval, dental clinic staff responsible for the prescription of the periodontal antibiotic treatment assigned each patient a code, which was previously generated randomly by another research team member. Depending on the method of treatment selection, this code consisted of a patient number and a letter A or B. Thus, 32 patients were randomly assigned to one method treatment group, while the other 32 were assigned to the other group.

Real-time biofilm growth monitoring

To select the most suitable transport media for periodontal biofilm samples, the subgingival plaque samples were collected in 2 mL of three different transport media, as indicated above, and homogenized by vortexing for 60 sec. Paper points were discarded, samples were vortexed again for 30 sec and split into three equal aliquots for biofilm growth in real-time either fresh or after 24 and 48 h (t=0, t=24, and t=48) of storage at room temperature. At each time point, the aliquots were centrifuged at 10.000 rpm for 3 minutes, supernatants were discarded, and bacterial pellets were resuspended with 400 μ L of BHI supplemented with vitamin K₁ (VitK₁) and hemin-menadione (reaching final concentrations of 0.2 mM and 0.5 mM, respectively). Two hundred microliters of the samples were used to monitor biofilm growth in the xCELLigence impedance monitoring system and the other 200 μ L of the




FIGURE 1

Diagram of the clinical study protocol: subgingival plaque samples from 64 individuals with severe periodontal disease were collected in VMGIII transport media and grown in an impedance system for monitoring periodontal biofilm growth in real time in the presence of antibiotics (Real-Time Culture). Derived biofilms were collected at 8h of growth for DNA extraction and 16S rRNA gene sequencing. In parallel, subgingival plaque samples from these 64 patients were used for standard hybridization-based periodontal pathogen quantification and associated antibiotic recommendations by the German Society of Periodontology (Sanz et al., 2020) (A). For the clinical trial, half of the patients were randomly treated with the antibiotic suggested by the RT-Culture system and the other half with the antibiotic prescribed based on the hybridization of periodontal pathogens. One and two months after antibiotic treatment, the improvement in clinical and microbiological parameters was evaluated for both study groups to assess disease progression (B).

suspensions were centrifuged, and the pellets stored at -20°C for DNA extraction and subsequent 16S rRNA gene sequencing.

For biofilm growth evaluation of periodontal plaque samples that were stored at room temperature for 0, 24 and 48h (t=0, t=24, and t=48h), the xCELLigence RTCA system was used as previously described (Žiemytė et al., 2020; Žiemytė et al., 2021). Briefly, 100 µL of BHI supplemented with VitK₁ and hemin-menadione were used for background measurements. Further, 100 µL of the subgingival plaque suspensions of the different time points were added into E-plate wells in duplicate. Then, an overlay of sterile mineral oil was gently added to the top of each well to favor anaerobic conditions. BHI supplemented with VitK₁ and hemin-menadione without bacterial inoculum was included in each experiment as a negative control. After that, E-plates were incubated in the RTCA system at 37°C, and periodontal biofilm growth was monitored for 8h and 24h, respectively. To analyze the bacterial composition of the formed periodontal biofilms at the bottom of the wells, supernatants were discarded, and biofilms were gently washed with PBS (phosphate buffer saline, pH=7.0) to eliminate

unattached bacterial cells. The adhered biofilm was collected using 200 µL of PBS, centrifuged, and the pellet stored at -20°C for further analysis. The same procedure was repeated with the periodontal samples stored at room temperature for 24h and 48h (t=24h and t=48h, respectively) in the different transport media.

Evaluation of periodontal biofilm susceptibility to antibiotics by real-time monitoring of biofilm growth

To identify the best individual treatment for each patient with severe periodontal disease, three systemic antibiotics commonly used in dental practice, namely amoxicillin, metronidazole and azithromycin (SIGMA), and the combination of amoxicillin and metronidazole, were tested, by evaluating their effect on biofilm formation of the subgingival plaque samples. Similarly to the experiments described above, the subgingival plaque was collected into 2 mL of VMG III transport media and vortexed for 60 seconds.

After that, paper-points were discarded, and samples were centrifuged at 10,000 rpm for 3 minutes. Hereafter, the pellet was resuspended with 2 mL of fresh BHI medium supplemented with VitK₁ and hemin-menadione (Hojo et al., 2007; Mira et al., 2019). All samples were divided into two equal aliquots. A pellet of 1 mL of each sample was used for DNA extraction and 16S rRNA gene sequencing, while the other 1 mL was used for biofilm growth in the RTCA system in the presence of different antibiotics.

To grow periodontal biofilms in the presence of conventional antibiotics in the RTCA system, 100 µL of each antibiotic diluted in BHI medium supplemented with VitK₁ and hemin-menadione reaching final concentrations of 8 mg/L for amoxicillin, 16 mg/L for metronidazole and 0.4 mg/L for azithromycin, respectively, were used for background measurements. These concentrations correspond to the maximum crevicular gingival fluid concentrations reached after oral administration of each antibiotic (Foulds et al., 1990; Kapoor et al., 2012; Matzneller et al., 2013; Mombelli and Walter, 2019). Then, 100 µL of homogenized periodontal samples were added into the wells, followed by a drop of mineral oil. Then, E-plates were incubated in the RTCA system at 37°C to monitor biofilm growth in real-time. After 8h of growth, supernatants were discarded, and bacterial cells attached to the E-plate surface were gently washed using PBS as described above, and the biofilms collected using 200 µL of PBS. Obtained pellets were stored at -20°C for further analysis. Two replicates of each condition and negative controls were included in each experiment. Biofilm growth dynamics graphs were plotted using the normalized average of the replicates.

DNA extraction, 16S rRNA gene sequencing and bioinformatic analyses

Genomic DNA from samples of the subgingival dental plaque collected before (initial inocula, t₀) and 1 and 2 months after antibiotic treatment (t₁ and t₂, respectively), and the corresponding biofilms grown in xCELLigence impedance system for eight hours (alone and in combination with antibiotics) was isolated using MagNA Pure LC DNA Isolation Kit III for Bacteria and Fungi (Roche Diagnostics) according to manufacturer's instructions. The 16S rRNA gene V3-V5 regions were amplified as previously described (Dzidic et al., 2018). The 16S rRNA gene Metagenomic Sequencing Library Preparation Illumina protocol (Part #15044223 Rev. A) was used to prepare an Illumina amplicon library. The amplicons were sequenced using 2x300 bp paired-end sequencing on an Illumina MiSeq Sequencer following the manufacturer's instructions (Illumina, San Diego, California, USA) at the Sequencing Service in FISABIO Institute (Valencia, Spain).

The obtained reads were analyzed as previously described using dada2 v1.16 (Callahan et al., 2016). Briefly, forward and reverse primers were removed, reads were quality-filtered by end-trimming and by a maximum number of expected errors. After that, reads were dereplicated, paired reads were merged, chimeras and host reads were removed, and the high-quality remaining reads were annotated using SILVA database v138.1 (Quast et al., 2013). The species annotation process in dada2 consists of two steps to ensure validity and robustness in taxonomic assignments. Initially, reads

undergo annotation using a Bayesian method, and acceptance is granted only if they achieve a 100% identity match. Subsequently, reads that did not receive species-level annotation in the first step but attained genus-level identification are subjected to a 97% identity filter. The taxonomic assignment is confirmed only if the difference in identity between the best and second-best matches is equal to or greater than 97%.

R programming language was used to compare statistically the proportion of bacteria between groups (CoreTeam, R 2018). Analysis of compositions of microbiomes with bias correction (ANCOM-BC) (Lin and Peddada, 2020) was used to normalize and compare the abundance of bacterial taxa. Multivariate analyses, including principal component analyses (PCA) and canonical correspondence analysis (CCA) were performed using vegan library (Oksanen et al., 2019). PCA loadings were represented using red arrows when indicated and computed as the correlation of the original variables with the first two principal components, whereas coordinates of observations or 'scores' were computed as the projection of the original observations on the first two principal components.

Based on the results from previous microbial-based studies, we grouped bacterial species considered periodontal pathogens into "disease-associated", whereas those that are known to be more abundant in healthy individuals were computed as "health-associated", following Perez-Chaparro et al. (Pérez-Chaparro et al., 2014). The list of bacteria included in these two groups is enumerated in Supplementary Table 1.

Data availability

Reads have been publicly deposited at the SRA database (accession number: PRJNA892459). All other datasets generated during and/or analysed during the current study are available from the corresponding authors.

Results

Evaluation of different transport media and growth conditions for periodontal biofilm cultivation


In order to select the most suitable transport media for biofilm samples from deep periodontal pockets, subgingival biofilms from five volunteers were collected in three different transport media (RTF, VMGIII and VMGIII Agar) and stored at room temperature for 0h, 24h and 48h (Supplementary Figure 1). Supplementary Figure 4A shows periodontal biofilm growth in real time after the preservation in RTF, VMGIII and VMGIII-Agar transport media as assessed by impedance measurements. The best recovery and biofilm growth were observed in RTF and VMG III media at 0h. However, in contrast to VMGIII, sample storage in RTF media for 24h and 48h resulted in biofilm growth delay and lower total biofilm mass accumulation compared to these parameters at 0h. Similarly, subgingival plaque storage in VMGIII-Agar reduced its capacity to

form biofilms, reaching lower CI values compared to those of VMGIII alone in all tested time points. In addition, 16S rRNA gene sequencing was used to compare the initial microbial composition of the inoculum (t=0) to that after 24 and 48h of storage in VMGIII transport media. 16S rRNA gene sequencing data revealed that VMGIII preserved periodontal bacteria diversity for at least 24h (Supplementary Figure 4B). Moreover, a similar bacterial composition was observed after 48h of storage, suggesting that VMGIII media could be appropriate for periodontal biofilm transportation. In addition, sequencing data indicated that grown biofilms derived from periodontal samples should be collected at 8h (not 24h) in order to preserve representative periodontal microbiota and avoid the overgrowth of *Streptococcus* genera (data not shown).

We also performed principal component analysis (PCA) comparing the microbial composition of 24 periodontal samples collected in VMGIII transport media (initial inoculum) to derived biofilms grown in the impedance system collected after 8h (Supplementary Figure 4C). Periodontal biofilms grown in the xCELLigence system contained a bacterial composition similar to the initial inocula. Although the increase in *Streptococcus* was observed in some cases, the biofilms grown *in vitro* contained a representative periodontal microbiota, including common periodontal pathogens such as *Tannerella*, *Treponema*, *Filifactor*, *Fusobacterium*, or *Treponema*, among others, as previously described (Mira et al., 2019).

The effect of conventional antibiotics on periodontal biofilm formation in real-time

Once the most suitable conditions for periodontal biofilm transportation and growth were established, we grew subgingival biofilms of 64 patients with periodontal disease *in vitro* in the presence of systemic antibiotics commonly used in clinical practice. Figure 2 illustrates the effect of the tested antibiotics on biofilm formation in six different susceptibility cases. As it can be observed in the figure, periodontal biofilms showed a sample-dependent effect. For example, amoxicillin showed a strong biofilm inhibition capacity in case E and a moderate inhibitory effect in cases A and B, while in other samples, the effect of this antibiotic had no inhibitory effect or even induced biofilm growth compared to the antibiotic-free cell control (case F). Although metronidazole favored biofilm formation in most of the cases (for example, Figures 2A, C, D, F), this antibiotic also showed the highest biofilm inhibition capacity in cases B and E. Given that there is compelling evidence that conjunctive antibiotic therapy usually results in better clinical outcomes (Feres et al., 2018), we also evaluated the effect of a combination of both antibiotics (amoxicillin and metronidazole added together) on subgingival biofilm formation. As shown in Figure 2, this combination was selected as the most efficient treatment strategy in case C, where periodontal biofilm development was inhibited by almost 50%



compared to the untreated control. However, similarly to metronidazole alone, this combination induced biofilm formation in the other cases. Finally, azithromycin, which is effective against many anaerobes including red-complex periodontopathogens, resulted in biofilm inhibition in case D, where other tested antibiotics resulted in biofilm growth induction. However, we have also noted some cases (2/64 of tested cases) where none of the tested antibiotics could halt biofilm formation (Figure 2F), suggesting that it might be necessary to test more antibiotics or their combinations in order to select an effective treatment for these patients. Finally, the data show that impedance-based antibiotic selection was consistent between 4 and 8 hours, supporting that suitable antibiotics can normally be chosen in less than four hours (see, for example, Figure 2E).

Antibiotic selection

After determining the most effective antibiotic treatment *in vitro* for each patient with both methodologies (RT-Culture by impedance measurements and hybridization), patients were divided in two groups: 32 patients were given the systemic antibiotic treatment selected by standard hybridization method, and the other 32 patients the antibiotic suggested by the impedance biofilm growth system (Figure 2). Supplementary Figure 5 shows the percentage of cases where each antibiotic was suggested in the two methodologies. The most common antibiotic therapy recommended by the impedance system was azithromycin (41.3% of the cases), while the hybridization method mainly suggested metronidazole (60.4% of cases). In addition, the impedance method recommended amoxicillin in 31.7%, metronidazole in 14.3% and their combination in 12.7% of the cases. In contrast to these results, the hybridization method selected amoxicillin in 15.1% of the cases, amoxicillin and metronidazole combination in 13.2% and azithromycin in 11.3% of the cases. Interestingly, both methodologies suggested the same antibiotic in only in 18.9% of the cases.

Clinical parameters before and after antibiotic therapy

In order to assess the clinical improvement observed in each group after antibiotic treatment, clinical parameters (periodontal pocket depth - PD, clinical attachment level - CAL, bleeding on probing - BOP and plaque presence (PLAQUE)) were evaluated at 2 months after the patients received antibiotic therapy (after treatment, AT) and compared these values to baseline (before treatment, BT). Clinical parameters of patients before and after periodontal treatment in the two groups are shown in Supplementary Table 2. Figure 3A shows the percentage of improvement of the clinical parameters after treatment with antibiotics selected by standard Hybridization and by culturing the subgingival sample in the impedance system (RT-Culture). All clinical parameters measured improved similarly in both groups, and was highest in BOP, which reached over a 50% reduction in the PCR hybridization group and over 60% reduction in

the RT-Culture group. Similarly, plaque presence was reduced considerably in both treatment groups. However, this reduction was significantly higher in the patients who received the antibiotic selected using the impedance-based system in comparison to the hybridization-based methodology. Supplementary Figure 6A shows the comparison between evaluated clinical parameters before and after treatment (BT and AT, respectively) for each study group. BOP, PD and CAL were significantly lower after antimicrobial therapy in both-hybridization and RT-Culture groups, while plaque levels were significantly reduced only in the group treated with the antibiotics suggested by the RT-Culture system (p -value=0.0001).

Figure 3B indicates that all antibiotics reduced all clinical parameters after 2 months of treatment. However, we detected differences in clinical parameters values before and after the treatment depending on the antibiotic used (Supplementary Figure 6B). For instance, amoxicillin, metronidazole, and azithromycin resulted in a significant decrease in PD (p -value < 0.005), which is a fundamental feature of periodontal disease. Similarly, these antibiotics also resulted in significantly decreased CAL and BOP. On the contrary, only amoxicillin and azithromycin showed a statistically significant decrease in the presence of dental plaque after treatment. Interestingly, no statistically significant decrease was observed in any of the evaluated clinical parameters when the patients were treated with the amoxicillin and metronidazole combination, which is among the most common antimicrobial therapies used to treat periodontitis.

Changes in microbial composition depending on antibiotic selection methodology and antibiotic treatment

On average, 112,000 16S rRNA reads/sample were sequenced, from which 47,600 reads/sample were annotated at the species level. Using the minimum number of reads annotated to the species level in a sample (22,900 reads), rarefaction analyses were performed, and the curves flattened after 20,000 sequences, showing that bacterial diversity was fully covered.

Chao1 richness index analysis showed that there were no significant differences in the estimated number of bacterial species between both groups before treatment (BT_hybridization vs. BT_RT-Culture) nor after treatment (AT_hybridization vs. AT_RT-Culture). On the other hand, a statistically significant reduction in the number of bacterial species after treatment was observed in the group treated with the antibiotic selected by the impedance system (Figure 4A). The CCA plot indicated similarities between the samples before treatment and showed that there were significant differences in the bacterial composition between both groups after antimicrobial therapy (ADONIS p -value=0.001) (Figure 4B). In addition, the relative abundance of red complex pathogens (*P. gingivalis*, *T. forsythia* and *T. denticola*) after treatment was decreased significantly in both treatment groups (adjusted p -value<0.001) (Supplementary Figure 7A). Interestingly, when this decrease was compared between both antibiotic selection methodologies, *P. gingivalis* had a significantly higher decrease in the group where the antibiotic treatment was prescribed based on




FIGURE 3 (A) Improvement of clinical parameters 2 months after periodontal treatment with antimicrobial therapy suggested by standard hybridization methodology and RT- culture. (B) Comparison of clinical parameters improvement 2 months after periodontal treatment among the different systemic antibiotics. Data are represented as a percentage of decrease (improvement) in different clinical parameters. PD - pocket depth; CAL- clinical attachment loss; BOP - bleeding on probing; PLAQUE – plaque presence; Amoxi - amoxicillin; Metro - metronidazole; AM - amoxicillin and metronidazole; Azitro – azithromycin. ***p-value* < 0.01.

the RT-Culture method compared to hybridization (Figure 4C) (*p-value*<0.05). Moreover, 16S rRNA gene sequencing data indicated that periodontal pathogens such as *F. nucleatum*, *Fretibacterium feline*, *Filifactor alocis* and other disease-associated bacteria decreased after the antibiotic treatment independently on the method used (Figure 4D; Supplementary Figure 7B and Supplementary Figure 8A, Supplementary Tables 2, 3). In addition, health-associated bacteria, including *Veillonella*, *Neisseria*, *Rothia*, *Streptococcus* and other genera increased after treatment in both groups (adjusted *p-value*<0.001) (Figure 4D; Supplementary Figure 7B, Supplementary Figure 8A, Supplementary Tables 2, 3).

Further, we compared whether bacterial richness and composition depended on the antibiotic used. The Chao1 index showed a notable decrease in bacterial richness after treatment with all antibiotics or their combination. However, this decrease was not statistically significant, except in the case of azithromycin (*p-value* < 0.001) (Figure 5A). In addition, when we compared the Chao1 index after the treatment among the different antibiotics, a significant decrease in bacterial richness was found in the group treated with azithromycin when compared to amoxicillin. (Figure 5A). Bacterial composition was also significantly affected by antibiotic treatment (Figure 5B). All tested antibiotics except the amoxicillin

metronidazole combination significantly reduced the abundance of red complex members (adjusted *p-value*<0.05) (Supplementary Figure 9A). Interestingly, when the reduction of these bacteria was compared between antibiotics, important differences were found. For instance, the combination of amoxicillin and metronidazole decreased *P. gingivalis* levels significantly more than when these two antibiotics were used separately (Figure 5C). In addition, *T. forsythia* was significantly more decreased after azithromycin treatment compared to amoxicillin. Similarly, *T. denticola* was significantly more reduced when azithromycin was used in comparison to metronidazole or to the amoxicillin – metronidazole combination (Figure 5C). Finally, when these three bacteria were combined into the so-called “red complex”, azithromycin significantly enhanced its reduction in comparison to amoxicillin or metronidazole (adjusted *p-value* <0.005) (Figure 5C). On the other hand, both the amoxicillin – metronidazole combination and azithromycin were very efficient not only against red complex pathogens but also against other pathogenic bacteria such as *Filifactor* or *Alloprevotella* spp (Supplementary Figure 8B, Supplementary Tables 4, 7). In contrast to periodontal disease-related pathogens, health-associated bacteria were observed to increase after treatment with all tested antibiotics (Figure 5D; Supplementary Figure 8B, Supplementary Figure 9B).




FIGURE 4
 Comparison of microbial composition under different antibiotic selection methodologies. **(A)** Alpha-diversity analysis (bacterial richness Chao1 index) comparison between the two antibiotic selection methods before and two months after treatment. **(B)** Canonical correspondence analyses showing the differences in microbial composition among groups and timepoints. **(C)** Changes in relative abundance of “red complex” periodontal pathogens and their members after treatment (expressed as fold change: before treatment/after treatment) for the two antibiotic selection methods. **(D)** Percentage of increase or decrease in periodontal disease-associated and health-associated bacteria two months after periodontal treatment. BT, before treatment; AT, after treatment; Amoxi, amoxicillin; Metro, metronidazole; AM, amoxicillin and metronidazole; Azitro, azithromycin. **p*-value < 0.05.

Clinical and microbiological outcomes one and two months after antibiotic treatment

Clinical evaluation showed that all clinical parameters significantly improved after one month of treatment (BT vs AT1M) in both methodologies (Supplementary Figure 10). No significant differences were observed when these parameters were compared between both methodologies. However, PD and CAL were reduced by up to 30% in both groups, while the improvement observed in BOP and plaque parameters was higher in the group treated with antibiotics selected with the RT-Culture system, reaching up to almost 80% reduction (Supplementary Figure 10). Further, the results showed that there were no statistically significant differences between the bacterial diversity before and after treatment with antibiotics prescribed by standard hybridization method at both time points (Figure 6A). On the contrary, sequencing data in the RT-Culture group showed that bacterial diversity was significantly lower (an indication of improvement in bacterial dysbiosis, as previously outlined by Griffen and collaborators (Griffen et al., 2012)) already at one month of treatment. In addition, even though bacterial diversity slightly increased after two months, the diversity values remained significantly lower

compared to the baseline. The CCA plot in Figure 6B shows the clustering of samples before and 1 and 2 months after treatment and suggests that microbial composition varied to a greater extent after one month of antibiotic therapy and returned closer to the initial state after 2 months of treatment in both groups. In addition, red complex pathogens also decreased in both treatment groups one month after treatment (Figure 6C). Interestingly, a significant reduction in *P. gingivalis* was found only in the RT-Culture group after two months of treatment (*p*-value=0.02) (Figure 4C). In general, most periodontal pathogens such as *Fusobacterium*, *Porphyromonas* and others were less abundant after one month of treatment when compared to two months (Supplementary Figures 11A–C). However, when the decrease of disease-associated microbes was compared between RT-Culture and hybridization groups after one month of treatment, a significantly reduction was found to be greater in the RT-Culture group (*p*-value=0.02) (Figure 6D). In addition, health-associated bacteria increased after one month of treatment in both treatment groups (Figure 6D and Supplementary Figure 12). Nevertheless, the abundance of health-associated bacteria was significantly higher one month after antibiotic treatment only in the group treated with the RT-Culture methodology (Supplementary Figure 12).




FIGURE 5
 Effect of different systemic antibiotic treatments in microbial composition *in vivo*. **(A)** Alpha-diversity (bacterial richness Chao1 index) analysis for different antibiotic treatment groups. **(B)** Canonical Correspondence Analysis (CCA) of microbial community composition of different treatment groups. **(C)** Changes in abundance of periodontal “red complex” cluster and their members after periodontal treatment and systemic antibiotic use (expressed as fold change: before treatment/after treatment). **(D)** Percentage of increase in disease-associated and health-associated bacteria two months after periodontal treatment for each antibiotic treatment group. BT, before treatment; AT, two months after treatment; Amoxi, amoxicillin; Metro, metronidazole; AM, amoxicillin and metronidazole; Azitro, azithromycin. **p*-value<0.05; ** adjusted *p*-value<0.05 and *** adjusted *p*-value<0.001.

Discussion

Periodontitis is an inflammatory disease that occurs due to prolonged inflammation of the gingiva, accumulation of opportunistic pathogens within subgingival dental plaque, their interaction with the host and the dysbiosis of microbiota embedded in dental biofilms (Zijngje et al., 2010; Jiao et al., 2014; Hajishengallis, 2015). The guidelines for antibiotic use as part of periodontal therapy vary among countries, and previous studies have reported that conventional antibiotics have different effects on periodontitis progression (Heller et al., 2011; Bizzarro et al., 2016; Chapple et al., 2018), emphasizing the need to choose an individualized therapy with the most appropriate antibiotic for each patient, which could result in better clinical outcomes. This has become especially relevant due to the alarming increase in bacterial antibiotic resistance and some organizations strongly discourage antibiotic use in periodontal patients except in specific cases (Sanz et al., 2020). When used, the choice of an antibiotic is normally made empirically, but several molecular techniques exist to select a personalized antibiotic therapy for periodontal patients. These techniques are based on DNA extraction from subgingival samples followed by quantification of periodontal bacteria by either qPCR or DNA hybridization with

species-specific probes (Vianna et al., 2005; Horz and Conrads, 2007). Based on the levels of periodontal pathogens, an antibiotic treatment protocol has been proposed (Sanz et al., 2020). However, these techniques have several limitations, such as the heterogeneity in antibiotic susceptibility among strains from the same species (Conrads et al., 2021), and they do not consider the potential effect of the EPS matrix on antibiotic resistance (Heller et al., 2011; Elashiry et al., 2021), or the complex interactions between different bacterial species within biofilms, which could derive in an antibiotic susceptibility pattern which is difficult to predict from bacterial composition (Feres et al., 2015; Villanueva-Castellote et al., 2023). An alternative to molecular methods is the culture of periodontal samples in agar plates in the presence of different antibiotics, in order to establish the overall antibiotic susceptibility of the bacterial community (Rams and Slots, 2023) but there are currently no standardized protocols to culture periodontal samples in biofilms and its efficacy compared to qPCR or molecular probes methodologies needs to be evaluated.

In the current manuscript, we have developed a fast method for culturing fresh periodontal samples with minimal sample processing that allows biofilm growth quantification in real time through impedance measurements. We show that VMGIII transport medium preserved initial bacterial composition and




FIGURE 6 Microbial composition of subgingival plaque samples before and one (AT1) or two months (AT2) after antibiotic treatment. **(A)** Alpha-diversity analysis (bacterial richness Chao1 index) one and two months after antibiotic treatment depending on the antibiotic selection method. **(B)** Canonical correspondence analyses showing the differences in microbial composition among treatment groups and timepoints. **(C)** Changes in abundance of the periodontal “red complex” cluster and their members one month after treatment (expressed as log fold change: before treatment/after treatment). **(D)** Percentage of disease-associated and health-associated bacteria increase or decrease one month after periodontal treatment, for both antibiotic selection methodologies. BT, Before treatment; AT, One month after treatment. **p*-value < 0.05.

viability to form biofilms for up to 48h. This suggests that periodontal pocket samples could be collected, transferred from the dental clinics and stored in this media at room temperature until further laboratory analysis. In addition, periodontal biofilms grown *in vitro* in the xCELLigence impedance system and collected at 8h showed representative bacterial composition similar to the initial inoculum, suggesting that BHI medium supplemented with VitK₁ and hemin-menadione is suitable for subgingival biofilm cultivation. It should be noted that under these conditions, *Streptococcus* showed an overgrowth compared to the initial inoculum, possibly due to the sugar concentration of the medium used, suggesting that BHI without sugar, added serum, artificial saliva or another medium (Naginyte et al., 2019) should be used as an alternative for unbiased periodontal biofilm cultivation in future studies.

Impedance-based measurements showed a remarkable variability in antibiotic susceptibility patterns for different patients with periodontal disease, and the antibiotic with best efficacy in reducing biofilm growth could not be predicted from the corresponding bacterial composition. Interestingly, the results in the current manuscript also highlight that amoxicillin and metronidazole combination often resulted in biofilm growth induction (Figure 6B) when compared to monotherapy in agreement with recent studies showing that antibiotic combinations often result in reduced antimicrobial efficacy (Lázár et al., 2022). It must be underlined

that antibiotic selection by the culturing method agreed with the hybridization method in less than 20% of the cases, indicating that it is very difficult to predict how a whole subgingival biofilm is going to react to a given antibiotic based on the levels of some bacterial species in the sample. In addition, impedance measures were capable of identifying two (2/64) patients for which the periodontal biofilms did not respond to any tested treatment, as all evaluated antibiotics induced biofilm growth, suggesting that other antibiotics or their combinations should be tested.

Half of the patients were prescribed the antibiotic selected by one of the two methods, and we compared the clinical and microbiological outcomes after one and two months in both study groups. The results showed that clinical parameters such as PD, CAL and BOP were improved in both groups after treatment independently of the antibiotic used, and the improvement in BOP was larger in the RT-Culture group (Figure 3A and Supplementary Figure 6A). However, a significant plaque reduction was only observed in the group treated with antibiotics selected by the impedance system (Figure 3A and Supplementary Figure 6A). Considering that the amount of plaque is an important factor for the development of the disease, the higher decrease in plaque accumulation in these individuals could represent a significant benefit for periodontal health. Nevertheless, the improvement in plaque accumulation should be confirmed in larger cohorts in the future. Interestingly, the improvement in clinical parameters did

not vary between antibiotics (Figure 3B), indicating that there was no antibiotic with overall superior performance. This suggests that antibiotic selection should be personalized for optimal effect.

Regarding microbiological parameters, 16S rRNA gene sequencing data showed that bacterial richness was significantly decreased only after the use of antibiotics selected by the RT-Culture system. This is a relevant feature as periodontitis is associated to higher numbers of bacterial species compared to the healthy condition (Camelo-Castillo et al., 2015; Chapple et al., 2018), probably derived from impairment of the immune system and from increased nutrient availability (Mira et al., 2017). The results of our study also indicated that periodontal therapies applied to the tested population decreased periodontal pathogenic taxa such as *Tannerella*, *Treponema*, *Fusobacterium*, or *Fillifactor* in both tested groups although the improvement was larger in the RT-Culture methodology (Figure 4C; Supplementary Figure S8A). *P. gingivalis*, which is considered a keystone periodontal pathogen, was significantly reduced in the group treated with antibiotics suggested by RT-Culture compared with the standard method (Figure 4C). In addition, an increase in health-associated taxa, including *Rothia*, *Neisseria*, *Veillonella* and others, was observed in both treatment groups, but was only significant at one month in the RT-culture group (Supplementary Figure 12, Supplementary Tables 2-8). Additionally, a significant reduction in disease-associated bacteria was observed only in the RT-Culture group after one month of treatment (Figure 6D).

In addition, our results also indicate that antibiotics' adjunctive influence on the subgingival microbiota depends on the antibiotic (Figure 5; Supplementary Figure 9). For instance, although all antibiotics inhibited red-complex pathogens the highest inhibition was observed by azithromycin (p -value < 0.01). Moreover, azithromycin was the only antibiotic which significantly decreased bacterial richness after treatment (Figure 5A). Similar findings were also described by other authors who suggested that the use of azithromycin as adjunctive therapy together with radicular scraping results in improved microbiological outcomes (Haffajee and Socransky, 1994; Oteo et al., 2010; Muniz et al., 2013). Furthermore, the comparison of clinical parameters and microbiological data indicates that most of the patients showed better outcomes one month after antibiotic therapy compared to two months (Figure 6; Supplementary Figures S10-12). This can be related to the ability of periodontal pathogens to persist inside periodontal pockets and regrow, causing inflammation once the treatment is ceased. Similar findings were observed in another study, which investigated the effect of mechanical treatment of subgingival plaque at several timepoints (Johnston et al., 2021). Another study by Bizzarro et al., also found that an antibiotic effect was seen on periodontal microbiota three, but not six months after treatment, suggesting that it is extremely difficult to eradicate periodontal pathogens from deep periodontal pockets (Bizzarro et al., 2016). It is also important to underline that smoking could potentially influence periodontal treatment outcomes, resulting in slower healing or recurring periodontal issues (Leite et al., 2018). However, in this work only 3 and 4 patients were smokers in the hybridization and real-time culture groups, and no significant differences were observed in any of the parameters studied between smokers and non-smokers.

Although many studies have been performed to investigate the critical factors in the occurrence and development of periodontitis and its treatment, to our knowledge, this is the first study which compares personalized antibiotic selection methods evaluating both clinical and microbiological outcomes. Multiple studies have shown that antibiotic use can improve the outcome of periodontal treatment (Feres et al., 2015; Mombelli and Walter, 2019). However, the clinical conditions under which antibiotics should be prescribed in periodontal patients are controversial and vary among countries (Horz and Conrads, 2007; Mombelli and Walter, 2019) and are beyond the scope of the current manuscript. In the cases where antibiotics are used, our data indicate that the use of impedance-based measurements of periodontal biofilms is a reliable antibiotic selection tool. The *in vivo* results indicate that patients treated with an antibiotic selected by this culture method showed equivalent and, in many cases, better clinical and microbiological outcomes when compared to a standard antibiotic selection methodology performed by hybridization technology. In addition, we show that this methodology is more selective, faster (allows the identification of best individual treatment in less than 4h) and cheaper when compared to standard antibiotic selection tools. Thus, we conclude that the Real-Time evaluation of periodontal biofilm growth could improve antibiotic treatment within a personalized dentistry framework. We believe that the use of personalized antibiotic selection in dentistry could not only contribute to a more rationale use of antimicrobials and reduce overall costs of healthcare but might also increase patients' willingness to treatment and favor the establishment of health-associated microorganisms in subgingival dental plaque (Chapple et al., 2018; Reddy et al., 2019).

Data availability statement

The data presented in the study are deposited in the SRA repository, accession number PRJNA892459.

Ethics statement

The studies involving humans were approved by Ethics Committee of the University of Valencia (Spain) (H1547805836517). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.

Author contributions

MŽ: Data curation, Formal analysis, Investigation, Methodology, Writing – original draft. AL-R: Methodology, Supervision, Visualization, Writing – original draft. MC-D: Data curation, Formal analysis, Methodology, Writing – original draft. MR-S: Methodology, Writing – original draft. AR: Methodology, Writing – original draft. MDF: Methodology, Supervision, Visualization, Writing – original draft, Validation, Writing –

review & editing. AM: Conceptualization, Funding acquisition, Methodology, Resources, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Spanish Ministry of Science, Innovation and Universities scholarship #FPU17/01302 to MŽ. The authors declare that this study received funding from Agilent Technologies. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fcimb.2023.1307380/full#supplementary-material>

SUPPLEMENTARY FIGURE 1

Workflow of experimental set up to evaluate transport media selection and growing conditions. Subgingival plaque samples (n=5) were collected and placed into RTF, VMGIII and VMG III Agar transport media using 10 sterile paper points and stored at room temperature for 0, 24 and 48h. After that, periodontal biofilms were grown in the impedance xCELLigence system, which measures biofilm growth in real-time. Formed biofilms were collected at 8h and 20h for DNA extraction and 16S rRNA gene Illumina sequencing to compare biofilm bacterial composition to the initial subgingival sample inoculum.

SUPPLEMENTARY FIGURE 2

Flow diagram of the clinical study design. Patients were referred to the University Dental Clinic and evaluated for eligibility criteria. On the first visit, personal data and clinical parameters (probing depth, clinical attachment level, bleeding on probing, and presence of plaque) were recorded, and a complete periapical radiographic series was performed. Subgingival plaque samples were collected with paper points and split in two: One into an empty Eppendorf tube for the quantification of periodontal pathogens by hybridization method; and the other was put in VMG-III transport medium and taken to the lab for evaluation of biofilm growth dynamics in the presence of different antibiotics, followed by determination of the bacterial

composition using 16S rRNA gene sequencing. On the second and third visits, non-surgical periodontal treatment (NSPT) was performed, and oral hygiene instructions (OHI) provided. On the third visit, the antibiotic indicated by one of the methodologies was prescribed randomly among patients. At one and two months (fourth and fifth visits), clinical parameters were reevaluated, and subgingival plaque samples were collected for 16S rRNA sequencing to assess the bacterial composition after treatment.

SUPPLEMENTARY FIGURE 3

Flow diagram of patient selection. Sixty-four patients who met inclusion criteria and agreed to participate in the study were allocated into two groups for antibiotic selection: RT-culture (n=32) and standard, commercially available hybridization (n=32). After the periodontal and antibiotic treatment, clinical and biological parameters were analyzed. Nine patients of the RT-culture group and two patients of the hybridization group were excluded from the statistical analysis when methodologies were compared because both approaches suggested the same antibiotic. In addition, one patient of the RT-culture group was not analysed, as the patient took a different antibiotic prescribed by another professional because of an additional infection and another two failed to attend their 2-month reevaluation visit to the dental clinic because of COVID. Similarly, six patients from the PCR-hybridization group did not attend all needed dental clinic visits, three did not receive antibiotics and five had incomplete antibiotic dosing.

SUPPLEMENTARY FIGURE 4

(A) *In vitro* periodontal biofilm growth in real-time as measured by impedance after preservation of the subgingival plaque in RTF, VMGIII and VMG III-Agar transport media. Samples of periodontal pockets were stored at room temperature for 0h, 24h and 48h. Then, subgingival samples biofilms were grown in the impedance-based monitoring xCELLigence system in real time. Biofilm growth was expressed as Cellular Index (CI), which correlates to total biofilm mass. Data are means of three replicates. SDs are not shown for clarity. (B) Bacterial composition in subgingival plaque samples collected from two different periodontal patients after storage in WMGIII transport media for 0, 24 and 48h. (C) Principal component analysis of subgingival plaque bacterial composition ("inocula", blue circles) collected in VMGIII growth media and the derived biofilms grown in the impedance xCELLigence system for 8h ("biofilms", white circles). The red arrows represent correlations of specific bacteria with the principal components (PC1 and PC2).

SUPPLEMENTARY FIGURE 5

Percentage of cases where each systemic antibiotic was prescribed by standard hybridization of periodontal pathogens and RT-culture methodologies. Amoxi – amoxicillin, Metro – metronidazole, AM – amoxicillin and metronidazole and Azitro – azithromycin. Black bars indicate cases when both methodologies suggested the use of the same conventional therapy (Shared).

SUPPLEMENTARY FIGURE 6

(A) Comparison of clinical parameters before and after 2 months of treatment. Percentage of examined tooth surfaces (top) and millimeters of pocket depth (bottom) before and after treatment in patients that used the antibiotic determined by hybridization or impedance (RT-culture). and (B) comparison in clinical parameters in the same patients, grouped by the antibiotic used. PD – pocket depth; CAL – clinical attachment loss; BOP – bleeding on probing; PLAQUE – plaque presence; BT – before treatment; AT – after treatment; Amoxi-amoxicillin; Metro-metronidazole; AM-amoxicillin and metronidazole; Azitro – azithromycin. * *p*-value < 0.05, ** *p*-value < 0.01 ** *p*-value < 0.005; ns – not significant.

SUPPLEMENTARY FIGURE 7

(A) Relative abundance of red complex pathogens (%) before and two months after antibiotic treatment in the groups receiving antibiotics selected by standard hybridization and RT-culture methodologies. (B) Relative abundance of disease and health-associated bacteria before and after two months after antibiotic treatment. BT – before treatment; AT – after treatment; * *p*.value < 0.05.

SUPPLEMENTARY FIGURE 8

Bacterial species mean abundance (%) in each group studied. (A) Hybridization vs. RT-Culture system. (B) Patients grouped by the antibiotic

used, regardless of the antibiotic selection methodology. BT - before treatment; AT - two months after treatment; Amoxi-amoxicillin; Metro-metronidazole; AM-amoxicillin and metronidazole; Azitro-azithromycin.

SUPPLEMENTARY FIGURE 9

(A) Relative abundance (%) of red-complex pathogens two months after periodontal treatment, compared by the prescribed antibiotic group. (B) Relative abundance (%) of disease-associated and health-associated bacteria two months after treatment. BT -before treatment; AT - after treatment; Amoxi - amoxicillin; Metro - metronidazole; AM - amoxicillin and metronidazole; Azitro - azithromycin. **p*-value < 0.05.

SUPPLEMENTARY FIGURE 10

Comparison of clinical parameters improvement (as a percentage of decrease) one and two months after antibiotic treatment according to the antimicrobial therapy (suggested by standard hybridization methodology or

RT-culture). PD - pocket depth; CAL- clinical attachment loss; BOP - bleeding on probing; PLAQUE -plaque presence. **p*-value < 0.05.

SUPPLEMENTARY FIGURE 11

Bacterial species mean abundance (%) in subgingival dental plaque from individuals before treatment (A), after one (B) and after two months (C) of periodontal treatment in combination with antibiotics. Each column represents a different patient. Only patients for which samples were available at all three timepoints are included.

SUPPLEMENTARY FIGURE 12

Health-associated species mean abundance (%) in individuals before periodontal treatment (BT) and after 1 (AT1M) or 2 (AT2M) months of treatment, for the two groups of treatment (selected by conventional hybridization and RT-Culture, respectively). **p*-value < 0.05.

References

Ainamo, J., and Bay, I. (1975). Problems and proposals for recording gingivitis and plaque. *Int. Dent. J.* 25, 229–235.

Aljehani, Y. A. (2014). Risk factors of periodontal disease: Review of the literature. *Int. J. Dent.* 2014. doi: 10.1155/2014/182513

Bizzarro, S., Laine, M. L., Buijs, M. J., Brandt, B. W., Crielaard, W., Loos, B. G., et al. (2016). Microbial profiles at baseline and not the use of antibiotics determine the clinical outcome of the treatment of chronic periodontitis. *Sci. Rep.* 6. doi: 10.1038/srep20205

Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., and Holmes, S. P. (2016). DADA2: High-resolution sample inference from Illumina amplicon data. *Nat. Methods* 13. doi: 10.1038/nmeth.3869

Camelo-Castillo, A. J., Mira, A., Pico, A., Nibali, L., Henderson, B., Donos, N., et al. (2015). Subgingival microbiota in health compared to periodontitis and the influence of smoking. *Front. Microbiol.* 6. doi: 10.3389/fmicb.2015.00119

Chapple, I. L. C., Mealey, B. L., Van Dyke, T. E., Bartold, P. M., Dommisch, H., Eickholz, P., et al. (2018). Periodontal health and gingival diseases and conditions on an intact and a reduced periodontium: Consensus report of workgroup 1 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *J. Periodontol.* 89 (Suppl 1), S74–S84. doi: 10.1002/JPER.17-0719

Chapple, I. L. C., van der Weijden, F., Doerfer, C., Herrera, D., Shapira, L., Polak, D., et al. (2015). Primary prevention of periodontitis: Managing gingivitis. *J. Clin. Periodontol.* 42 (Suppl 16), S71–S76. doi: 10.1111/jcpe.12366

Cecchi, V., and Pascolo, G. (2018). Microbiological response to periodontal therapy: A retrospective study. *Open Dent. J.* 12, 837–845. doi: 10.2174/1874210601812010837

Conrads, G., Klomp, T., Deng, D., Wenzler, J. S., Braun, A., and Abdelbary, M. M. H. (2021). The antimicrobial susceptibility of porphyromonas gingivalis: genetic repertoire, global phenotype, and review of the literature. *Antibiotics* 10. doi: 10.3390/antibiotics10121438

CoreTeam, R (2018). *R Development Core Team. R: A language and environment for statistical computing* (Vienna, Austria: R Foundation for Statistical Computing), 2014.

Dahlén, G., Pipattananagovit, P., Rosling, B., and Möller, J. R. (1993). A comparison of two transport media for saliva and subgingival samples. *Oral. Microbiol. Immunol.* 8, 375–382. doi: 10.1111/j.1399-302X.1993.tb00614.x

Darveau, R. P. (2010). Periodontitis: A polymicrobial disruption of host homeostasis. *Nat. Rev. Microbiol.* 8 (7), 481–490. doi: 10.1038/nrmicro2337

Dzidic, M., Collado, M. C., Abrahamsson, T., Artacho, A., Stensson, M., Jenmalm, M. C., et al. (2018). Oral microbiome development during childhood: an ecological succession influenced by postnatal factors and associated with tooth decay. *ISME J.* 12, 2292–2306. doi: 10.1038/s41396-018-0204-z

Elashiry, M., Morandini, A. C., Cornelius Timothy, C. J., Ghaly, M., and Cutler, C. W. (2021). Selective antimicrobial therapies for periodontitis: Win the “battle and the war”. *Int. J. Mol. Sci.* 22. doi: 10.3390/ijms22126459

Feres, M., Figueiredo, L. C., Soares, G. M. S., and Faveri, M. (2015). Systemic antibiotics in the treatment of periodontitis. *Periodontol.* 2000 67, 131–186. doi: 10.1111/prd.12075

Feres, M., Retamal-Valdes, B., Mestnik, M. J., de Figueiredo, L. C., Faveri, M., Duarte, P. M., et al. (2018). The ideal time of systemic metronidazole and amoxicillin administration in the treatment of severe periodontitis: Study protocol for a randomized controlled trial. *Trials* 19. doi: 10.1186/s13063-018-2540-8

Ferrer, M. D., Lamarche, B., and Mira, A. (2007). *Studying bacterial biofilms using cellular impedance. xCELLigence®Real-time cell analyzers.* (ACEA Biosciences, Inc), 1–6.

Foulds, G., Shepard, R. M., and Johnson, R. B. (1990). The pharmacokinetics of azithromycin in human serum and tissues. *J. Antimicrob. Chemother.* 25, 73–82. doi: 10.1093/jac/25.suppl_A.73

Griffen, A. L., Beall, C. J., Campbell, J. H., Firestone, N. D., Kumar, P. S., Yang, Z. K., et al. (2012). Distinct and complex bacterial profiles in human periodontitis and health revealed by 16S pyrosequencing. *ISME J.* 6, 1176–1185. doi: 10.1038/ismej.2011.191

Haffajee, A. D., and Socransky, S. S. (1994). Microbial etiological agents of destructive periodontal diseases. *Periodontol.* 2000 5, 78–111. doi: 10.1111/j.1600-0757.1994.tb00020.x

Hajishengallis, G. (2015). Periodontitis: From microbial immune subversion to systemic inflammation. *Nat. Rev. Immunol.* 15 (1), 30–44. doi: 10.1038/nri3785

Heller, D., Varela, V. M., E Silva-Senem, M. X., Torres, M. C. B., Feres-Filho, E. J., and Colombo, A. P. V. (2011). Impact of systemic antimicrobials combined with anti-infective mechanical debridement on the microbiota of generalized aggressive periodontitis: A 6-month RCT. *J. Clin. Periodontol.* 38, 355–364. doi: 10.1111/j.1600-051X.2011.01707.x

Hojo, K., Nagaoka, S., Murata, S., Taketomo, N., Ohshima, T., and Maeda, N. (2007). Reduction of vitamin K concentration by salivary Bifidobacterium strains and their possible nutritional competition with Porphyromonas gingivalis. *J. Appl. Microbiol.* 103 (5), 1969–1974. doi: 10.1111/j.1365-2672.2007.03436.x

Horz, H. P., and Conrads, G. (2007). Diagnosis and anti-infective therapy of periodontitis. *Expert Rev. Anti Infect. Ther.* 5, 703–715. doi: 10.1586/14787210.5.4.703

Irshad, M., Alam, M. K., Alawneh, A., Alhadi, M. A., Alhadi, A. A., Almunajem, Y. S., et al. (2020). Characterization and antimicrobial susceptibility of pathogens associated with periodontal abscess. *Antibiotics* 9, 654. doi: 10.3390/antibiotics9100654

Isola, G. (2020). Antibiotics and antimicrobials for treatment of the oral microbiota: Myths and facts in research and clinical practice. *Antibiotics* 9, 95. doi: 10.3390/antibiotics9020095

Jakubovics, N. S., Goodman, S. D., Mashburn-Warren, L., Stafford, G. P., and Cieplik, F. (2021). The dental plaque biofilm matrix. *Periodontol.* 2000 86 (1), 32–56. doi: 10.1111/prd.12361

Jiao, Y., Hasegawa, M., and Inohara, N. (2014). The role of oral pathobionts in dysbiosis during periodontitis development. *J. Dent. Res.* 93 (6), 539–546. doi: 10.1177/0022034514528212

Johnston, W., Rosier, B. T., Artacho, A., Paterson, M., Piel, K., Delaney, C., et al. (2021). Mechanical biofilm disruption causes microbial and immunological shifts in periodontitis patients. *Sci. Rep.* 11 (1), 9796. doi: 10.1038/s41598-021-89002-z

Kapoor, A., Malhotra, R., Grover, V., and Grover, D. (2012). Systemic antibiotic therapy in periodontics. *Dent. Res. J. (Isfahan)* 9 (5), 505–515. doi: 10.4103/1735-3327.104866

Ko, T. J., Byrd, K. M., and Kim, S. A. (2021). The chairside periodontal diagnostic toolkit: Past, present, and future. *Diagnostics* 11. doi: 10.3390/diagnostics11060932

Kuboniwa, M., and Lamont, R. J. (2010). Subgingival biofilm formation. *Periodontol.* 2000 52 (1), 38–52. doi: 10.1111/j.1600-0757.2009.00311.x

Lamont, R. J., Koo, H., and Hajishengallis, G. (2018). The oral microbiota: dynamic communities and host interactions. *Nat. Rev. Microbiol.* 16, 745–759. doi: 10.1038/s41579-018-0089-x

Lázár, V., Snitser, O., Barkan, D., and Kishony, R. (2022). Antibiotic combinations reduce Staphylococcus aureus clearance. *Nature* 610, 540–546. doi: 10.1038/s41586-022-05260-5

Leite, F. R. M., Nascimento, G. G., Scheutz, F., and López, R. (2018). Effect of smoking on periodontitis: A systematic review and meta-regression. *Am. J. Prev. Med.* 54 (6), 831–841. doi: 10.1016/j.amepre.2018.02.014

Li, X., Kolltveit, K. M., Tronstad, L., and Olsen, I. (2000). Systemic diseases caused by oral infection. *Clin. Microbiol. Rev.* 13 (4), 547–558. doi: 10.1128/CMR.13.4.547-558.2000

Lin, H., and Peddada, S. (2020). Analysis of compositions of microbiomes with bias correction. *Nat. Commun.* 11. doi: 10.1038/s41467-020-17041-7

Lu, H., He, L., Xu, J., Song, W., Feng, X., Zhao, Y., et al. (2020). Well-maintained patients with a history of periodontitis still harbor a more dysbiotic microbiome than health. *J. Periodontol.* 91, 8–15. doi: 10.1002/JPER.19-0498

Lu, M., Xuan, S., and Wang, Z. (2019). Oral microbiota: A new view of body health. *Food Sci. Hum. Wellness* 8 (1), 8–15. doi: 10.1016/j.fshw.2018.12.001

Marcenes, W., Kassebaum, N. J., Bernabé, E., Flaxman, A., Naghavi, M., Lopez, A., et al. (2013). Global burden of oral conditions in 1990–2010: A systematic analysis. *J. Dent. Res.* 92 (7), 592–597. doi: 10.1177/0022034513490168

Matilla-Cuenca, L., Gil, C., Cuesta, S., Rapún-Araiz, B., Žiemytė, M., Mira, A., et al. (2020). Antibiofilm activity of flavonoids on staphylococcal biofilms through targeting BAP amyloids. *Sci. Rep.* 10 (1), 18968. doi: 10.1038/s41598-020-75929-2

Matzner, P., Krasniqi, S., Kinzig, M., Sörgel, F., Hüttner, S., Lackner, E., et al. (2013). Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. *Antimicrob. Agents Chemother.* 57 (4), 1736–1742. doi: 10.1128/AAC.02011-12

Mira, A., Buetas, E., Rosier, B., Mazurel, D., Villanueva-Castellote, Á., Llana, C., et al. (2019). Development of an *in vitro* system to study oral biofilms in real time through impedance technology: validation and potential applications. *J. Oral Microbiol.* 11 (1), 1609838. doi: 10.1080/20002297.2019.1609838

Mira, A., Simon-Soro, A., and Curtis, M. A. (2017). Role of microbial communities in the pathogenesis of periodontal diseases and caries. *J. Clin. Periodontol.* 44, S23–S38. doi: 10.1111/jcpe.12671

Mombelli, A., and Walter, C. (2019). Antibiotics in periodontics. *Swiss Dent. J.* 129 (10), 835–838.

Muniz, F. W. M. G., De Oliveira, C. C., De Sousa Carvalho, R., Moreira, M. M. S. M., De Moraes, M. E. A., and Martins, R. S. (2013). Azithromycin: A new concept in adjuvant treatment of periodontitis. *Eur. J. Pharmacol.* 705 (1–3), 135–139. doi: 10.1016/j.ejphar.2013.02.044

Naginyte, M., Do, T., Meade, J., Devine, D. A., and Marsh, P. D. (2019). Enrichment of periodontal pathogens from the biofilms of healthy adults. *Sci. Rep.* 9, 5491. doi: 10.1038/s41598-019-41882-y

Nilsson, H., Berglund, J. S., and Renvert, S. (2018). Periodontitis, tooth loss and cognitive functions among older adults. *Clin. Oral Investig.* 22 (5), 2103–2109. doi: 10.1007/s00784-017-2307-8

Oksanen, J., Kindt, R., Legendre, P., O'Hara, B., Simpson, G. L., Solymos, P. M., et al. (2019). Community Ecology Package. R package version 2.4-2. *Community Ecol. Packag.* 2, 5–6.

O'Leary, T. J., Drake, R. B., and Naylor, J. E. (1972). The plaque control record. *J. Periodontol.* 43 (1), 38. doi: 10.1902/jop.1972.43.1.38

Oteo, A., Herrera, D., Figuero, E., O'Connor, A., González, I., and Sanz, M. (2010). Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis-associated periodontitis: A pilot study. *J. Clin. Periodontol.* 37 (11), 1005–1015. doi: 10.1111/j.1600-051X.2010.01607.x

Papapanou, P. N., Sanz, M., Buduneli, N., Dietrich, T., Feres, M., Fine, D. H., et al. (2018). Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. *J. Periodontol.* 89, S173–S182. doi: 10.1002/JPER.17-0721

Pérez-Chaparro, P. J., Gonçalves, C., Figueiredo, L. C., Faveri, M., Lobão, E., Tamashiro, N., et al. (2014). Newly identified pathogens associated with periodontitis: A systematic review. *J. Dent. Res.* 93. doi: 10.1177/0022034514542468

Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., et al. (2013). The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. *Nucleic Acids Res.* 41. doi: 10.1093/nar/gks1219

Rams, T. E., and Slots, J. (2023). Antimicrobial chemotherapy for recalcitrant severe human periodontitis. *Antibiotics* 12, 1–18. doi: 10.3390/antibiotics12020265

Reddy, M., Shetty, S., and Vannala, V. (2019). Embracing personalized medicine in dentistry. *J. Pharm. Bioallied Sci.* 11, S92–S96. doi: 10.4103/JPBS.JPBS_297_18

Rosier, B. T., Marsh, P. D., and Mira, A. (2018). Resilience of the oral microbiota in health: mechanisms that prevent dysbiosis. *J. Dent. Res.* 97 (4), 371–380. doi: 10.1177/0022034517742139

Santigli, E., Leitner, E., Wimmer, G., Kessler, H. H., Feierl, G., Grube, M., et al. (2016). Accuracy of commercial kits and published primer pairs for the detection of periodontopathogens. *Clin. Oral Investig.* 20 (9), 2515–2528. doi: 10.1007/s00784-016-1748-9

Sanz, M., Herrera, D., Kebschull, M., Chapple, I., Jepsen, S., Beglundh, T., et al. (2020). Treatment of stage I–III periodontitis—The EFP S3 level clinical practice guideline. *J. Clin. Periodontol.* 47 (Suppl 22), 4–60. doi: 10.1111/jcpe.13290

Seneviratne, C. J., Jin, L., and Samaranyake, L. P. (2008). Biofilm lifestyle of Candida: A mini review. *Oral Dis.* 14 (7), 582–590. doi: 10.1111/j.1601-0825.2007.01424.x

Teughels, W., Feres, M., Oud, V., Martín, C., Matesanz, P., and Herrera, D. (2020). Adjunctive effect of systemic antimicrobials in periodontitis therapy: A systematic review and meta-analysis. *J. Clin. Periodontol.* 47, 257–281. doi: 10.1111/jcpe.13264

Urbán, E., Terhes, G., Radnai, M., Gorzó, I., and Nagy, E. (2010). Detection of periodontopathogenic bacteria in pregnant women by traditional anaerobic culture method and by a commercial molecular genetic method. *Anaerobe* 16 (3), 283–288. doi: 10.1016/j.anaerobe.2010.02.005

Van der Weijden, F., Rijnen, M., and Valkenburg, C. (2021). Comparison of three qPCR-based commercial tests for detection of periodontal pathogens. *Sci. Rep.* 11 (1), 6141. doi: 10.1038/s41598-021-85305-3

Vianna, M. E., Horz, H. P., Gomes, B. P. F. A., and Conrads, G. (2005). Microarrays complement culture methods for identification of bacteria in endodontic infections. *Oral Microbiol. Immunol.* 20 (4), 253–258. doi: 10.1111/j.1399-302X.2005.00221.x

Villanueva-Castellote, Á., Llana Puy, C., Carda-Diéguez, M., Mira, Á., and Ferrer, M. D. (2023). Ex vivo evaluation of antibiotic sensitivity in samples from endodontic infections. *J. Oral Microbiol.* 15 (1), 2160536. doi: 10.1080/20002297.2022.2160536

Weinberg, M. A., and Eskow, R. N. (2003). Periodontal terminology revisited. *J. Periodontol.* 74 (4), 563–565. doi: 10.1902/jop.2003.74.4.563

Žiemytė, M., Carda-Diéguez, M., Rodríguez-Díaz, J. C., Ventero, M. P., Mira, A., and Ferrer, M. D. (2021). Real-time monitoring of Pseudomonas aeruginosa biofilm growth dynamics and persister cells' eradication. *Emerg. Microbes Infect.* 10, 2062–2075. doi: 10.1080/22221751.2021.1994355

Žiemytė, M., Rodríguez-Díaz, J. C., Ventero, M. P., Mira, A., and Ferrer, M. D. (2020). Effect of dalbavancin on staphylococcal biofilms when administered alone or in combination with biofilm-detaching compounds. *Front. Microbiol.* 11. doi: 10.3389/fmicb.2020.00553

Zijge, V., Van Leeuwen, M. B. M., Degener, J. E., Abbas, F., Thurnheer, T., Gmür, R., et al. (2010). Oral biofilm architecture on natural teeth. *PLoS One* 5. doi: 10.1371/journal.pone.0009321